Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials

Eitemau Tebyg

• Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
  gan: Sambunaris, Angelo, et al.
  Cyhoeddwyd: (2014)
• A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
  gan: Sambunaris, Angelo, et al.
  Cyhoeddwyd: (2014)
• The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
  gan: Montgomery, Stuart A., et al.
  Cyhoeddwyd: (2014)
• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  gan: Gommoll, Carl P., et al.
  Cyhoeddwyd: (2014)
• Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories
  gan: Cutler, Andrew J., et al.
  Cyhoeddwyd: (2015)